The trial results add to a growing body of clinical evidence that suggests popular GLP-1 drugs such as Lilly’s Zepbound and Novo Nordisk’s (NOVOb.CO), Wegovy have medical benefits beyond ...

Pfizer Inc (NYSE:PFE) is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer ...

Novo Nordisk and Eli Lilly's dominance over the budding weight loss drug market could eventually face threats from formidable ...

Innovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli Lilly's diabetes and heart ...

Lilly’s revenue miss in the quarter “reflects a lack of capacity, rather than a problem with Lilly product demand,” BMO Capital Markets analyst Evan David Seigerman said in a note Tuesday.

Eli Lilly ( LLY 5.72%), a leading pharmaceutical company, released its Q1 financials on April 30, and the numbers showcased a robust performance that exceeded expectations on the earnings front.

Shares of Eli Lilly (LLY) are soaring in Tuesday's trading session after the company raised its full-year guidance, driven by ...

Investors will likely seek commentary around the production to meet increased demand and Eli Lilly's partnership with Amazon to deliver some of its prescription medications. Eli Lilly (LLY ...

The trial results add to a growing body of clinical evidence that suggests popular GLP-1 drugs such as Lilly's Zepbound and Novo Nordisk's (NOVOb.CO) , opens new tab Wegovy have medical benefits ...

Lilly's revenue miss in the quarter "reflects a lack of capacity, rather than a problem with Lilly product demand," BMO Capital Markets analyst Evan David Seigerman said in a note Tuesday.

Lilly's shares have risen 26% since January. Lilly evaluated its GLP-1 drug called tirzepatide, sold as Zepbound for obesity and Mounjaro for type 2 diabetes, in patients with obstructive sleep ...